FDA Approves ZYN as Less Harmful Than Cigarettes: What It Means in 2026

On 30 June 2026, the U.S. Food and Drug Administration (FDA) issued modified risk granted orders for 20 ZYN nicotine pouch products — the first time any nicotine pouch brand in the world has received this level of regulatory recognition. The approved claim is precise: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." This is not a minor regulatory footnote. It is the highest harm-reduction credential any nicotine pouch has ever earned in any major market, and it has significant implications for the global industry in 2026.

• Key Takeaways
• The FDA issued MRTP (Modified Risk Tobacco Product) orders for 20 ZYN products on 30 June 2026 — the first ever for a nicotine pouch brand.
• Approved products: 10 flavours in both 3 mg and 6 mg — Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen.
• ZYN may now legally claim it is less harmful than cigarettes for six specific diseases including mouth cancer, heart disease and stroke — in the US market.
• An MRTP is a significantly harder standard than a standard marketing authorisation: it requires proof that the claim benefits the population as a whole, not just individual users.
• European regulators are moving in a different direction — EU TPD3 consultation closes 14 August 2026 and could bring flavour bans and restrictions across all 27 member states by 2029–2030.

What Is an FDA MRTP Order — and How Is It Different From a Standard Approval?

Most nicotine pouch products in the US market hold a PMTA (Pre-Market Tobacco Product Authorisation) — the baseline licence required to legally sell the product. ZYN received its PMTA on 16 January 2025. A PMTA establishes that a product is "appropriate for the protection of public health." That is the floor, not the ceiling.

An MRTP order goes substantially further. To receive one, a manufacturer must demonstrate three things to the FDA's satisfaction: that the specific risk-reduction claim is scientifically accurate and well-supported, that consumers correctly understand what the claim means (and do not interpret it as a guarantee of safety), and that marketing the product with the claim benefits the population as a whole — accounting for both smokers switching and non-smokers who might start because of reduced-risk messaging.

That last requirement — the population benefit test — is what makes MRTP orders so rare. The FDA must be satisfied that the net effect of expanded marketing with the claim will be positive across all consumer groups. Only a handful of products have ever cleared this bar. Swedish Match's moist snuff products (General Snus) were the first, in 2019. ZYN is now the first nicotine pouch brand in history to join that list — a distinction that took years of clinical studies, consumer research and FDA scientific review to achieve.

Which 20 ZYN Products Are Covered?

The MRTP orders cover exactly 10 flavours, each in 3 mg and 6 mg strengths — 20 products in total. Higher-strength ZYN products (11 mg) were not included in this batch. The orders were issued to Swedish Match USA, Inc., a subsidiary of Philip Morris International (PMI).

ZYN Flavour	3 mg Approved	6 mg Approved
ZYN Chill	Yes	Yes
ZYN Cinnamon	Yes	Yes
ZYN Citrus	Yes	Yes
ZYN Coffee	Yes	Yes
ZYN Cool Mint	Yes	Yes
ZYN Menthol	Yes	Yes
ZYN Peppermint	Yes	Yes
ZYN Smooth	Yes	Yes
ZYN Spearmint	Yes	Yes
ZYN Wintergreen	Yes	Yes

The orders expire in five years, after which Swedish Match must reapply. The FDA also has the authority to withdraw orders early if post-market surveillance reveals concerns — for example, significant youth uptake linked to MRTP marketing. Swedish Match is required to conduct ongoing studies tracking user behaviour and how consumers interpret the risk-reduction claim in real-world conditions.

What the Approved Claim Actually Says

The exact wording authorised by the FDA is: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." Every word in that sentence matters. It is a comparative claim — ZYN versus cigarettes — not an absolute safety claim.

The six diseases listed represent the principal cigarette-caused conditions supported by the strongest causal evidence in the scientific literature. By naming them explicitly rather than using vague harm-reduction language, the FDA has grounded the claim in verifiable biology. As the FDA's official announcement states, the agency reviewed the relative health risks of the products, consumer understanding of the claims, youth risk data, and the potential population-wide impact before granting the orders.

What the claim does not say is equally important. It does not declare ZYN safe. It does not recommend ZYN for non-smokers. It does not claim nicotine itself is harmless. The MRTP framework is specifically designed for adult smokers considering a switch — and that context is embedded in every aspect of how the claim can be legally used in US advertising and packaging.

What This Means for the European Nicotine Pouch Market

The FDA decision has no direct legal effect in Europe. Regulation here falls under the EU's Tobacco Products Directive (TPD) and national law. ZYN cannot use the MRTP marketing claim on European packaging or in EU advertising. But the decision lands at a critical moment for European regulation — and the contrast could not be sharper.

The EU opened public consultation on TPD3 in June 2026, with a deadline of 14 August 2026. A legislative proposal is expected in Q4 2026, with rules potentially taking effect around 2029–2030. Unlike the FDA's evidence-based approval of ZYN's harm-reduction claim, the TPD3 consultation is being driven heavily by public health advocates calling for flavour bans, plain packaging, and nicotine concentration caps for pouches. Twelve EU member states, led by Ireland, formally pushed for flavour restrictions at the June 2026 Health Council meeting.

Meanwhile, Denmark has already acted. Since April 2026, Denmark allows only tobacco and menthol flavours in nicotine replacement products, with a strict 9 mg nicotine cap per pouch and mandatory plain packaging. This is precisely the direction the TPD3 consultation may push for all 27 member states.

The regulatory divergence between the US and EU matters for industry trajectory. PMI's smoke-free strategy — which reached 43 million smoke-free product users globally as of June 2026 — is being validated by the world's most demanding regulator in the US, even as European regulators consider restrictions. For European buyers using ZYN 3 mg or 6 mg, the products now FDA-approved with a reduced-risk claim are exactly the strengths most popular in European markets. The science is the same on both sides of the Atlantic — it is the regulatory philosophy that differs.

Where Does This Leave VELO, LOOP, XQS, ZEUS and Other Brands?

The MRTP orders apply only to ZYN products, and only in the US. No other nicotine pouch brand — including VELO (British American Tobacco), LOOP, XQS, ZEUS, C.R.E.A.M or KUMA — holds equivalent US MRTP status. BAT has invested heavily in VELO's harm-reduction narrative and has a substantial US PMTA filing, but has not received an MRTP order.

Brand	Parent Company	US PMTA	MRTP Order	Primary Market
ZYN	Swedish Match / PMI	Jan 2025	Jun 2026	US + Global
VELO	British American Tobacco	Yes	None	Europe-first
LOOP	NGP Capital	EU-regulated	N/A	Europe
XQS	Winnington AB	EU-regulated	N/A	Europe
ZEUS	Vivasnus	EU-regulated	N/A	Europe
C.R.E.A.M	GN Tobacco	EU-regulated	N/A	Europe

For everyday European buyers, this regulatory distinction does not change which product best suits your needs. VELO 11 mg, LOOP Mint Mania 9.4 mg, XQS Arctic Mint and the full range at The Snus Outlet's 2026 picks are unaffected by US FDA orders. The practical difference is in long-term market positioning and the credibility that ZYN and PMI have now built with the world's toughest regulatory agency.

What the FDA decision does signal for European users is that the science behind nicotine pouches — and ZYN's specific safety profile in particular — has now been tested and validated at the highest level. PMI applied for the MRTP in 2022. The review took four years. The evidence base required to pass included clinical studies, consumer perception surveys, youth access data and population-level modelling. That body of evidence does not disappear simply because European regulators have not yet reviewed it under TPD3.

Frequently Asked Questions

Does the FDA approval mean ZYN is safe to use?

No. The MRTP order permits a specific comparative claim: ZYN carries a lower risk than cigarettes for six named diseases. It does not mean ZYN is risk-free, harmless, or appropriate for non-smokers. Nicotine is addictive. The MRTP is designed for adult smokers considering a switch, not for people who have never used nicotine.

Can ZYN market with the FDA claim in Europe?

No. The MRTP orders are US-specific and issued under FDA authority. European packaging and advertising are governed by the EU Tobacco Products Directive and national laws, which currently do not permit reduced-risk claims of this type for nicotine pouches. EU rules may change under TPD3, expected post-2029.

Which ZYN strengths and flavours received MRTP approval?

The 20 approved products cover 10 flavours — Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint and Wintergreen — each in 3 mg and 6 mg. ZYN 11 mg products were not included in this set of orders.

How does the MRTP order affect ZYN's European availability?

It does not directly affect European availability. ZYN is sold across the EU under existing national regulatory frameworks. The MRTP is a US marketing authorisation, not a product approval affecting import or sale rights in Europe. ZYN remains fully available to European buyers in 3 mg, 6 mg and 11 mg strengths.

Will other brands like VELO or LOOP apply for MRTP approval?

There is no public announcement from BAT, LOOP or other European brands of MRTP applications. The process takes years and requires substantial clinical investment. PMI began its ZYN MRTP application in 2022 and received approval in 2026 — a four-year process. European-first brands may pursue this eventually, particularly if EU TPD3 creates pressure to build regulatory credibility.

Final Thoughts

The FDA's 30 June 2026 MRTP decision is the most significant regulatory milestone the nicotine pouch category has ever reached. For four years, Swedish Match submitted data, ran consumer perception studies and responded to FDA queries — and the outcome is a claim that no pouch brand has ever been permitted to make in any major regulated market. Europe will form its own view through TPD3, but the science underpinning the FDA's decision is global. Browse the full range of nicotine pouch deals at The Snus Outlet, including ZYN 3 mg and 6 mg — the exact strengths now FDA-approved with reduced-risk status. Free EU shipping on orders over €99.